Michael Reilly - Concepedia

Concepedia

Author

Michael Reilly

GlaxoSmithKline (United States)

Also Known As

M Reilly, M. REILLY, M. Reilly, M.A. Reilly, Maeve A. Reilly, Michael A Reilly, Michael A. Reilly, Michael Reilly, Reilly, Michael A.

56

Publications

3.1K

Citations

26

H-Index

52

Concepts

All Affiliations

GlaxoSmithKline (United States)Binghamton University Merck & Co., Inc., Rahway, NJ, USA (United States)GlaxoSmithKline (United Kingdom)MSD (UK) Limited (United Kingdom)

MR

About

Michael Reilly is an author at GlaxoSmithKline (United States) specializing in pharmacology, medicine, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	1.9K
2	Natural Sciences	9	9	781
3	Biochemistry	8	8	317
4	Engineering	3	3	80
5	Biomolecular Engineering	3	3	80

Michael Reilly

×

30

Publications

3.1K

Citations

25

H-Index

	Year	Citations
Design of amidobenzimidazole STING receptor agonists with systemic activity Joshi M. Ramanjulu, G. Scott Pesiridis, Jingsong Yang, Nature Systemic ActivityMedicineMechanism Of ActionPharmacological AgentPharmacotherapy	2018	803
Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases Philip A. Harris, Scott B. Berger, Jae Uk Jeong, Journal of Medicinal Chemistry Drug TargetImmunologyCell DeathPharmacotherapyInflammation	2017	464
RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer Wei Wang, Jill M. Marinis, Allison M. Beal, Cancer Cell Cancer ImmunosurveillancePancreatic CancerMedicineImmunologyTumor Immunity	2018	245
Extended pharmacodynamic responses observed upon PROTAC-mediated degradation of RIPK2 Alina Mares, Afjal H. Miah, Ian E. Smith, Communications Biology	2020	209
Characterization of GSK′963: a structurally distinct, potent and selective inhibitor of RIP1 kinase SB Berger, Philip A. Harris, Rakesh Nagilla, Cell Death Discovery	2015	145
Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of <scp>RIPK</scp>1 inhibitor <scp>GSK</scp>2982772 in healthy volunteers Kathleen Weisel, Nicola Scott, Debra Tompson, Pharmacology Research & Perspectives	2017	123
The Identification and Pharmacological Characterization of 6-( <i>tert</i> -Butylsulfonyl)- <i>N</i> -(5-fluoro-1 <i>H</i> -indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase Pamela A. Haile, Bartholomew J. Votta, Robert W. Marquis, Journal of Medicinal Chemistry	2016	122
Quantitative Measurement of Changes in Amyloid-β(40) in the Rat Brain and Cerebrospinal Fluid following Treatment with the γ-Secretase Inhibitor LY-411575 [N2-[(2 S)-2-(3,5-Difluorophenyl)-2-hydroxyethanoyl]-N1-[(7 S)-5-methyl-6-oxo-6,7-dihydro-5 H-dibenzo[b,d]azepin-7-yl]-l-alaninamide] Jonathan D. Best, Mark T. Jay, Franklin Otu, Journal of Pharmacology and Experimental Therapeutics	2005	98
The Novel γ Secretase Inhibitor N-[cis-4-[(4-Chlorophenyl)sulfonyl]-4-(2,5-difluorophenyl)cyclohexyl]-1,1,1-trifluoromethanesulfonamide (MRK-560) Reduces Amyloid Plaque Deposition without Evidence of Notch-Related Pathology in the Tg2576 Mouse Jonathan D. Best, David W. Smith, Michael Reilly, Journal of Pharmacology and Experimental Therapeutics	2006	83
Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer Philip A. Harris, Jill M. Marinis, John D. Lich, ACS Medicinal Chemistry Letters	2019	79

Page 1